<DOC>
	<DOCNO>NCT01885624</DOCNO>
	<brief_summary>The purpose study assess safety tolerability ascend dose TAB08 single i.v . infusion adult healthy volunteer . Additionally assessed infusion speed tolerability , pharmacokinetics pharmacodynamics TAB08 single i.v . infusion explore TAB mechanism-of-action biomarkers .</brief_summary>
	<brief_title>Open Label Phase 1 Pharmacokinetics Tolerability Study Single TAB08 Administration Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Adult man age 18 40 year , agree use adequate contraception . Body mass least 60 kg BMI within 2027 Volunteer good physical mental health , per medical history assessment result Volunteer 's laboratory value normal ( clinically significant per Investigator discretion ) screening , include baseline cytokine level per RESTORE test result Volunteer sign informed concent . Any chronic relapsing illness medical history Any abnormal assessment laboratory result screening , clinically significant per Investigator discretion Active tuberculosis time screen Any acute illness time study enrollment Any blood donation within 4 week Study Day 1 Positive result HBsAG , Hepatitis C , HIV Continuous use af medication Use medication within 72 hour study drug infusion Use investigational treatment within 4 week screening , within period 5 halflives investigational treatment , whichever longer High inflammatory cytokine level per RESTORE test result ex vivo PBMC testing</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>TAB08</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>